Company intelligence / Profile preview
Apellis Pharmaceuticals
Waltham, Massachusetts, United Statesapellis.ca ↗
- Ownership
- Public · APLS
- Employees
- ~900
- Development stage
- Commercial
01
Overview
Apellis has pioneered targeted inhibition of C3 within the complement cascade. Its lead product, pegcetacoplan, is approved as EMPAVELI for PNH and as SYFOVRE for geographic atrophy. The company’s pipeline includes additional indications for pegcetacoplan as well as next-generation RNA-based therapies, gene-edited approaches with partners like Beam Therapeutics, and oral inhibitors. Clinical results have established efficacy for PNH and GA with ongoing pivotal trials in nephrology and hematology.
- Therapeutic areas
- OphthalmologyHematologyNeurologyNephrology
- Modalities
- Small molecules (notably pegcetacoplan)Synthetic peptidesGene therapiessiRNA therapiesBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Sobi — global co-development/ex-U.S. commercialization rights for systemic pegcetacoplanBeam Therapeutics — gene-editing collaborations on FcRn/complement targetsAdditional academic collaborations not detailed publicly
04
Financials
- Market cap
- $5.3B
- Total revenue
- $268.3M
- Enterprise value
- $5.3B
Beyond the preview
Go deeper on Apellis Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apellis Pharmaceuticals.